Recombinant alpha 2 interferon in the treatment of chronic myeloproliferative disorders
Bonaccorso, R.; Teresi, M.; Gebbia, V.; Tambone Reyes, M.; Tinnirello, D.; Di Marco, P.; Citarrella, P.; Mansueto, S.
Journal of ChemoTherapy 1(4 Suppl): 1266-1268
1989
ISSN/ISBN: 1120-009X PMID: 16312860 Document Number: 328075
Document emailed within 1 workday
Related Documents
Linkesch, W.; Gisslinger, H.; Ludwig, H.; Flener, R.; Sinzinger, H. 1985: Therapy with interferon (recombinant IFN-alpha-2C) in myeloproliferative diseases with severe thrombocytoses Acta Medica Austriaca 12(5): 123-127Marinucci, G.; Hassan, G.; Di Giacomo, C.; Barlattani, A.; Costa, F.; Rasshofer, R.; Roggendorf, M. 1991: Long term treatment of chronic delta hepatitis with alpha recombinant interferon Progress in Clinical and Biological Research 364: 405-410
Carreño, V.; Porres, J.C.; Ruiz-Moreno, M.; Gutiez, J.; Bartolomé, F.J. 1991: A controlled study of treatment with recombinant interferon alpha of chronic hepatitis due to the B virus in childhood Revista Espanola de Enfermedades Digestivas: Organo Oficial de la Sociedad Espanola de Patologia Digestiva 79(1): 24-28
Kissová, J. 2019: Interferon-alpha in the treatment of myeloproliferative diseases Vnitrni Lekarstvi 65(11): 699-703
Ballarino, P.; Castello, G.; Lerza, R. 1994: Interferon-alpha in the treatment of myeloproliferative syndromes Recenti Progressi in Medicina 85(11): 546-550
Utili, R.; Sagnelli, E.; Galanti, B.; Aprea, L.; Cesaro, G.; Digilio, L.; Filippini, P.; Felaco, F.M.; Gaeta, G.B.; Marrone, A. 1991: Prolonged treatment of children with chronic hepatitis B with recombinant alpha 2a-interferon: a controlled, randomized study American Journal of Gastroenterology 86(3): 327-330
Mels, G.C.; Roffi, L.; Antonelli, G.; Bellati, G.; Pacchetti, S.; Di Nolfo, M.A.; Panizzuti, F.; Moretti, G.; Piperno, A.; Pozzi, M. 1993: Lymphoblastoid interferon in patients with chronic nAnB hepatitis showing relapse during recombinant alpha interferon therapy Progress in Clinical and Biological Research 382: 359-364
Perrillo, R.P.; Regenstein, F.G.; Peters, M.G.; DeSchryver-Kecskemeti, K.; Bodicky, C.J.; Campbell, C.R.; Kuhns, M.C. 1988: Prednisone withdrawal followed by recombinant alpha interferon in the treatment of chronic type B hepatitis. A randomized, controlled trial Annals of Internal Medicine 109(2): 95-100
Sréter, L.; Kárteszi, M.; Fehér, J.; Lutz, D. 1988: Serum type-III-procollagen and laminin concentration after interferon therapy in chronic myeloproliferative disorders Acta Medica Hungarica 45(3-4): 323-328
Rostaing, L.; Izopet, J.; Baron, E.; Duffaut, M.; Puel, J.; Durand, D. 1995: Treatment of chronic hepatitis C with recombinant alpha 2b interferon in kidney transplant recipients: preliminary results and side effects Transplantation Proceedings 27(1): 948-950
Corbillet, V.; Celerier, P.; Lebon, P.; Litoux, P.; Dreno, B. 1995: Development of interferon antibodies during the treatment of skin diseases with low-dose recombinant interferon alpha-2a Annales de Medecine Interne 146(6): 399-403
Coutant, G.; Blétry, O.; Prin, L.; Hauteville, D.; de Puyfontaine, O.; Abgrall, J.F.; Godeau, P. 1993: Treatment of hypereosinophilic syndromes of myeloproliferative expression with the combination of hydroxyurea and interferon alpha. Apropos of 7 cases Annales de Medecine Interne 144(4): 243-250
Jurincic-Winkler, C.; Horlbeck, R.; Klippel, K.F. 1993: Combination therapy with recombinant interferon alpha-21 (rIFN alpha 2a) and recombinant interleukin 2 (rIL-2) in metastatic renal cell cancer Wiener Klinische Wochenschrift 105(10): 271-276
Musch, E.; Högemann, B.; Gerritzen, A.; Fischer, H.P.; Wiese, M.; Kruis, W.; Malek, M.; Gugler, R.; Schmidt, G.; Huchzermeyer, H.; Gerlach, U.; Dengler, H.J.; Sauerbruch, T. 1998: Phase Ii clinical trial of combined natural interferon-beta plus recombinant interferon-gamma treatment of chronic hepatitis B Hepato-Gastroenterology 45(24): 2282-2294
Bresci, G.; Parisi, G.; Banti, S.; Bertoni, M. 1993: Therapy of active chronic hepatitis with recombinant alpha 2b-interferon: an 18 month follow-up European Journal of Medicine 2(6): 349-352
Balan, V.; Nelson, D.R.; Sulkowski, M.S.; Everson, G.T.; Lambiase, L.R.; Wiesner, R.H.; Dickson, R.C.; Garcia, A.; Moore, P.A.; Yu, R.; Subramanian, G.M. 2006: Modulation of interferon-specific gene expression by albumin-interferon-alpha in interferon-alpha-experienced patients with chronic hepatitis C Antiviral Therapy 11(7): 901-908
Fischl, M.A.; Uttamchandani, R.B.; Resnick, L.; Agarwal, R.; Fletcher, M.A.; Patrone-Reese, J.; Dearmas, L.; Chidekel, J.; McCann, M.; Myers, M. 1991: A phase I study of recombinant human interferon-alpha 2a or human lymphoblastoid interferon-alpha n1 and concomitant zidovudine in patients with AIDS-related Kaposi's sarcoma Journal of Acquired Immune Deficiency Syndromes 4(1): 1-10
Uchaikin, V.; Cherednichenko, T.; Malinovskaya, V.; Orlova, T.; Kovalev, O.; Kharlamova, F.; Chaplygina, G.; Konev, V.; Voronina, F.; Delenian, N. 2000: Use of recombinant alpha-2b-interferon in combination with antioxidants in the form of rectal suppositories (viferon) in children with chronic hepatitides B and C Acta Virologica 44(2): 79-83
Fedorchenko, S.V. 1994: Can chronic hepatitis B patients overcome resistance to antiviral therapy due to production of antibodies to recombinant alpha-2-interferon? Voprosy Virusologii 39(5): 218-220
Romeril, K.R.; Carter, J.M.; Green, G.J.; Beard, M.E.; Heaton, D.C.; Newhook, C.H.; Gibbons, S.S.; Reddy, J. 1989: Treatment of hairy cell leukaemia with recombinant alpha interferon New Zealand Medical Journal 102(866): 186-188